Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.

Journal of molecular modeling - 28 Dec 2022

Cao Shu, Tan Changbin, Fei Anhua, Hu Gangqiang, Fu Ming, Lv Jun

Abstract excerpt

OBJECTIVE: RET (rearranged during transfection) kinase, as a transmembrane receptor tyrosine kinase, is a therapeutic target for several human cancer such as non-small cell lung cancer (NSCLC) and thyroid cancer. Pralsetinib is a recently approved drug for the treatment of RET-driven NSCLC and thyroid cancers. A single point mutation G810C at the C-lobe of the RET kinase causes pralsetinib resistance to this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Dynamics Simulation

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Source

Identifiers

PMID: 36576611
DOI: 10.1007/s00894-022-05429-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.PMID 36576611Read ↗

How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.Semantic proximity Read ↗

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read ↗

Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Semantic proximity Read ↗

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.Semantic proximity Read ↗

In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.Semantic proximity Read ↗

Characterization of wild-type and mutated RET proto- oncogene associated with familial medullary thyroid cancer.Semantic proximity Read ↗

Modeling the Effects of Single Nucleotide Polymorphisms (SNPs) on the Structure and Function of the Human RET Gene: An In Silico Study.Semantic proximity Read ↗

A Molecular Dynamics Protocol for Rapid Prediction of EGFR Overactivation and Its Application to the Rare Mutations S768I, S768N, D761NSemantic proximity Read ↗

Computational biophysical characterization of the effect of gatekeeper mutations on the binding of ponatinib to the FGFR kinase.Semantic proximity Read ↗

Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis.Semantic proximity Read ↗

Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutationsSemantic proximity Read ↗

Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.